痰热清注射液佐治肿块期浆细胞性乳腺炎42例

目的 观察痰热清注射液佐治肿块期肝经蕴热型浆细胞性乳腺炎（plasma cell mastitis，PCM）的临床疗效。方法 将83例肿块期肝经蕴热型PCM患者随机分为观察组42例，对照组41例，对照组采用外敷如意金黄膏，口服泼尼松片，观察组在此基础上加用静脉滴注痰热清注射液，比较两组患者治疗前后乳腺肿块大小、临床疗效及不良反应。结果 两组治疗后肿块均较治疗前明显缩小（P＜0.05），观察组肿块缩小程度大于对照组，差异有统计学意义（P＜0.05）；两组临床疗效的分布比较，差异具有统计学意义（P<0.05）；治疗过程中两组均未见明显不良反应，两组复发率比较，差异无统计学意义（P＞0.05）。结论 痰热清注射液对肿块期肝经蕴热型PCM具有较好的辅助治疗作用。

Clinical Effect of Tanreqing Injection as Adjuvant Therapy for Mass-stage Plasma Cell Mastitis: An Analysis of 42 Cases

Objective To investigate the clinical effect of Tanreqing Injection as the adjuvant therapy for mass-stage plasma cell mastitis (PCM) with the syndrome of accumulated heat in the liver meridian. Methods A total of 83 patients with mass-stage PCM with the syndrome of accumulated heat in the liver meridian were randomly divided into observation group with 42 patients and control group with 41 patients. The patients in the control group were given external application of Ruyi Jinhuang Plaster and oral prednisone tablets, and those in the observation group were given intravenous dripping of Tanreqing Injection in addition to the treatment for the control group. The size of breast mass before and after treatment, clinical outcome, and adverse events were compared between the two groups. Results After treatment, both groups had significant reductions in the size of breast mass (P<0.05), and the observation group had a significantly greater reduction compared with the control group (P<0.05). There was a significant difference in the distribution of clinical outcomes between the two groups (P<0.05). There were no marked adverse events in either group during treatment, and there was no significant difference in recurrence rate between the two groups (P>0.05). Conclusion As an adjuvant therapy, Tanreqing Injection has a good clinical effect in the treatment of PCM with the syndrome of accumulated heat in the liver meridian.